MARKET

GLTO

GLTO

Galecto Inc.
NASDAQ
27.46
+4.57
+19.97%
After Hours: 26.66 -0.8 -2.91% 19:58 12/05 EST
OPEN
22.17
PREV CLOSE
22.89
HIGH
27.85
LOW
22.17
VOLUME
132.61K
TURNOVER
--
52 WEEK HIGH
33.60
52 WEEK LOW
2.010
MARKET CAP
43.73M
P/E (TTM)
-2.2873
1D
5D
1M
3M
1Y
5Y
1D
Galecto Price Target Announced at $32.00/Share by Guggenheim
Dow Jones · 4d ago
Guggenheim Initiates Coverage On Galecto with Buy Rating, Announces Price Target of $32
Benzinga · 4d ago
Analysts’ Top Healthcare Picks: Hinge Health, Inc. Class A (HNGE), Scholar Rock Holding (SRRK)
TipRanks · 4d ago
Galecto initiated with a Buy at Guggenheim on DMR-001 potential
TipRanks · 4d ago
Weekly Report: what happened at GLTO last week (1124-1128)?
Weekly Report · 4d ago
Galecto initiated with a Buy at Guggenheim
TipRanks · 5d ago
Weekly Report: what happened at GLTO last week (1117-1121)?
Weekly Report · 11/24 09:30
Galecto Inc. Files Initial Beneficial Ownership Statement Naming Fairmount Funds Management LLC
Reuters · 11/18 02:49
More
About GLTO
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Webull offers Galecto Inc stock information, including NASDAQ: GLTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLTO stock methods without spending real money on the virtual paper trading platform.